Hemogenyx Pharmaceuticals PLC Announces Allotment of Shares
- Wall Street slides as virus spike hits travel stocks
- Kansas City Southern (KSU) Soars as Bidding War Brews After Canadian National Railway (CNI) Makes a $33.7 Billion Offer
- Analysts Positive, Raise PTs as IBM (IBM) Tops Market Estimates and Reaffirms Guidance
- Boeing (BA) Down 3% After CFO - Aged 54 - Retires, Seen as an 'Odd' Move
- Tesla (TSLA): Problems in China Mounting as Communist Party Officials Ask Company to 'Respect Chinese Consumers and Comply with Local Laws'
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
LONDON, UK / ACCESSWIRE / February 10, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has allotted 7,741,935 new ordinary shares of £0.01 each in the Company ("Ordinary Shares") in settlement of an arrangement fee due to the arranger of the Financing Facility announced on 18 November 18 2020 and approved by the Company's shareholders on 6 January 2021, under which an initial draw down of Â£12,000,000 was made on 3 February 2021.
An application has been made to the London Stock Exchange Main Market and admission of the new Ordinary Shares to trading is expected on or around 11 February 2021 ("Admission"). The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.
Total Voting Rights
Following Admission of the new Ordinary Shares, the Company will have 441,378,190 Ordinary Shares of Â£0.01 each in issue with voting rights. The Company does not hold any shares in treasury. This figure may then be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
Hemogenyx Pharmaceuticals plc
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
Peter Redmond, Director
SP Angel Corporate Finance LLP
Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited
Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NextGen TV demo shows how journalists can use technology to fight misinformation
- Copel Announces Filing of 20-F Form
- KWESST Announces U.S. Patent Award for Phantom(TM), Qualifies for Government Programs
Create E-mail Alert Related CategoriesAccesswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!